Hawaii
In 2001, the Hawaii State Laboratory performed gonorrhea culture and antimicrobial susceptibility tests on specimens from 265 (44%) of 605 reported gonorrhea cases. Patients seeking care at the public sexually transmitted disease (STD) clinic accounted for 44% (117 of 265) of these isolates. Overall, QRNG accounted for 20% (53 of 265) of gonococcal isolates tested, compared with 11% in 2000 and 10% in 1999 ( Figure 1 ). In 2001, 36% (19 of 53) of QRNG infections were among STD clinic patients. Editorial Note: These data demonstrate that in 2001, QRNG prevalence increased in Hawaii and in California, where the epidemiology of QRNG varies within the state. In California, antimicrobial susceptibility data are available for a smaller proportion of reported gonorrhea cases than in Hawaii (6% versus 44%). Demographic data suggest that this low proportion might limit the generalizability of California's findings: patients with susceptibility-tested isolates in California were more likely to be male, older, and white, and to have their condition diagnosed in STD clinics than were other gonorrhea patients. However, the data from California indicate that QRNG has reached the continental United States, increasing the risk for its spread. Sporadic cases of QRNG have been identified in other states through GISP and non-GISP reporting, but no sustained increase in QRNG >1% has been identified in any other state (3) . Increases in QRNG in California and Hawaii highlight the ongoing need for monitoring antimicrobial susceptibilities of gonococcal isolates throughout the United States.
CDC recommends that fluoroquinolones not be used to treat gonococcal infections acquired in Asia, where QRNG prevalence exceeds 40% (5) ; in the Pacific Islands, including Hawaii; in California; and in other areas with increased prevalence of fluoroquinolone resistance (6) . The recommended treatment options for persons who might have acquired infection in those areas are cefixime (7), ceftriaxone, or spectinomycin. To select appropriate gonorrhea treatment in areas outside Hawaii and California, clinicians should ask suspected gonorrhea patients about their recent travel history and that of their sex partners (8) .
Treatment of gonorrhea with fluoroquinolones can continue in areas where the prevalence of resistance is <1% (9) . In areas where resistance is >1%, health departments making local treatment recommendations for gonorrhea also should consider other local factors such as the overall prevalence of gonorrhea, the availability of antimicrobial susceptibility data, and the cost of various diagnostic and treatment options (10) . Fluoroquinolones remain an important gonorrhea treatment option in the United States because they are inexpensive and easy to administer. In addition, their use might decrease use of cephalosporins and delay the development of cephalosporin resistance.
As part of effective gonorrhea control, state health departments should monitor local gonococcal antimicrobial susceptibility prevalence routinely to assist in developing local treatment recommendations. Symptomatic treatment failures are not a reliable indicator of emerging antimicrobial resistance because gonococcal infections, especially in women, are frequently asymptomatic. In 2001, a survey of STD project areas found that nonculture gonococcal tests were used widely and that approximately half of project areas had antimicrobial susceptibility data (3) . Because nonculture tests cannot provide antimicrobial susceptibility results, local gonococcal culture capacity should be maintained. The antimicrobial susceptibility testing panel should, at a minimum, include a fluoroquinolone, cefixime, ceftriaxone, spectinomycin, azithromycin, and any other drugs in local use for gonorrhea treatment.
In cases of persistent gonococcal infection after treatment, clinicians should consider performing culture and antimicrobial susceptibility testing. In areas where fluoroquinolones are used for treating gonorrhea and small numbers of patients with QRNG are identified, health departments should notify and treat partners of patients with known QRNG to minimize the spread of resistance. 
April-June 2000 Outbreak
A total of 47 confirmed cases of S. Poona infections with indistinguishable PFGE patterns were identified from California (26), Washington (10), Nevada (five), New Mexico (three), Oregon (two), and Colorado (one), with illness onset occurring during April 14-June 2. The median age of ill persons was 7 years (range: 1-95 years); 28 (60%) patients were aged <10 years, and nine (19%) were aged >60 years. Twenty-four (51%) patients were male and nine (19%) were hospitalized.
A matched case-control study was conducted; 20 casepatients were matched by age category to 37 community controls. A case was defined as laboratory-confirmed infection with S. Poona of the outbreak PFGE pattern in a person with illness onset during April-June. By multivariable modeling, illness was associated only with eating cantaloupe (matched odds ratio [MOR]=6.7; 95% confidence interval [CI]=1.3-34.0), with 16 (80%) case-patients versus seven (19%) controls reporting eating cantaloupe. Cantaloupe was purchased either pre-cut or whole.
April-May 2001 Outbreak
In April, an initial cluster of S. Poona was identified in California. Isolates had a rare biochemical trait, the inability to produce hydrogen sulfide (H 2 S), and PFGE patterns that were indistinguishable. A total of 50 cases of H 2 S-negative S. Poona infections were identified in residents of California (28), Washington (eight), Nevada (seven), Arizona (six), and Oregon (one). Demographic and illness-history data from the 28 California patients indicated that illness onset occurred during April 6-May 28. The age distribution was bimodal; the 19 children had a median age of 3 years (range: 1-5 years) and the nine adults had a median age of 80 years (range: 39-91 years). Fifteen (54%) patients were female. Ten (36%) patients were bacteremic; one infant girl had S. Poona isolated from a urine specimen. Nine (33%) patients were hospitalized, and two patients (a man aged 78 years and a woman aged 91 years) died with Salmonella septicemia.
A matched case-control study was conducted; 11 casepatients from California (seven), Nevada (two), Arizona (one), and Washington (one) were matched by age category to 19 community controls. Case-patients had laboratory-confirmed infections of the outbreak strain of H 2 S-negative S. Poona and illness onset during the first 2 weeks of April. Illness was associated only with eating cantaloupe (MOR=7.4; 95% CI=1.0-178.0). Eight (80%) case-patients and six (33%) controls recalled eating cantaloupe. Cantaloupe was purchased either pre-cut or whole.
March-May 2002 Outbreak
A total of 58 cases with S. Poona isolates with indistinguishable PFGE patterns were identified in California (21), Washington (nine), Oregon (five), British Columbia (four), Colorado (three), Nevada (three), Manitoba (two), Missouri (two), Ontario (two), Saskatchewan (two), Texas (two), Arkansas (one), Minnesota (one), and Vermont (one). Illness onset occurred during March 30-May 31; the median age of patients was 6 years (range: 4 months-91 years); 32 (55%) were aged <10 years, and 11 (19%) were aged >60 years. A total of 31 (55%) were female. Ten patients were hospitalized.
A matched case-control study was conducted; 27 casepatients were matched by age category to 54 community controls. A case was defined as S. Poona infection with the outbreak PFGE pattern in a person aged >2 years with illness onset during March 15-May 3. The only exposure significantly associated with illness was eating cantaloupe; 20 (74%) case-patients recalled eating cantaloupe compared with 11 (20%) controls (MOR=15.5; 95% CI=3.3-125.0). Casepatients (50%) were more likely than controls (13%) to eat cantaloupe purchased whole (MOR=5.8; 95% CI=1.6-23. 3) or to eat cantaloupe in a fruit salad or as a garnish (28% versus 5%) (MOR=6.5; 95% CI=1.2-63.0). No other factors were significantly associated with illness.
Traceback and Regulatory Action
FDA, in conjunction with state and provincial food regulatory agencies, conducted traceback investigations of cantaloupe purchased by patients in all three outbreaks. In each instance, point-of-sale sources of cantaloupe were traced back to shippers and then to farms in Mexico. In response to the 2000 and 2001 outbreaks, FDA conducted on-farm investigations in Mexico and concluded that measures were not in place to minimize microbial contamination in the growing, harvesting, packaging, and cooling of cantaloupe. Possible (5, 6) . The three outbreaks attributed to S. Poona-contaminated cantaloupe traced to Mexican farms suggest the possibility of a unique natural reservoir in the Mexican farm environment, possibly from reptiles such as iguanas drawn to feed on melon crops that enter the packing sheds and contaminate the equipment. Subsequently, water used in the washing and cooling process might spread the contamination.
FDA provides information about the decontamination of melons to the retail industry, food-service establishments, and commercial processors of pre-cut melon (7, 8) . The use of sodium hypochlorite or other permitted antimicrobials in combination with brushing is recommended. The potential for microbial contamination also might be reduced by using only good-quality fruit that is free from open wounds or defects that might allow bacteria to contaminate the interior of the fruit (9) . Additional research is needed to determine the effectiveness of consumer produce-washing practices. Consumers should be sure that fresh-cut melons are refrigerated or surrounded by ice; leftover cut melons should be discarded if left at room temperature for >2 hours. Additional information for consumers is available at http://www.fda.gov/bbs/ topics/answers/2002/ans01167.html.
On October 28, 2002, in response to the three outbreaks during 2000-2002 and analytical results from the sampling of imported Mexican cantaloupe, FDA issued an import alert that detains all cantaloupe from Mexico offered for entry at all U.S. ports. FDA will continue to work with the Mexican government on a food-safety program for the production, packing, and shipping of fresh cantaloupe. The Mexican government is developing a certification program based on sound agricultural and manufacturing practices that would allow FDA to identify farms that have adopted and implemented such a food-safety program.
Enterovirus SurveillanceUnited States, 2000-2001
Enteroviruses are common viruses associated with diverse clinical manifestations ranging from mild febrile illness to severe and potentially fatal syndromes including aseptic meningitis, encephalitis, neonatal systemic enteroviral disease, and paralytic poliomyelitis (1) . A total of 64 enterovirus serotypes are recognized, including 61 nonpolio enteroviruses (2)*. Individual serotypes have different temporal patterns of circulation and often are associated with different clinical manifestations (1, 4) . This report describes temporal trends in reported enterovirus infections in the United States during 2000-2001, including widespread activity of two serotypes (echoviruses 13 and 18) that previously were detected rarely. Monitoring of circulating enterovirus serotypes helped identify these two agents as the primary causes of aseptic meningitis outbreaks in the United States in 2001. Further improvements in timeliness of reporting and geographic representation of the system are needed to allow more complete surveillance for enteroviruses.
Other than paralytic polio, diseases associated with enterovirus infections, including aseptic meningitis, are not nationally notifiable in the United States. The National Enterovirus Surveillance System (NESS) collects information on enterovirus serotypes and monitors temporal and geographic trends to help public health officials recognize and control outbreaks of enteroviral disease. Enterovirus detections from human specimens that are submitted for testing to participating laboratories are reported voluntarily to NESS along with basic demographic information, specimen type, and date of collection.
The to underestimating the number of individual enteroviruses, reports with unknown serotypes were excluded from the analysis of serotype distribution. During 2000-2001, echovirus 18 and echovirus 13 were the predominant serotypes, accounting for 22.0% and 20.8% respectively of the reports with an identified serotype, followed by coxsackievirus B5 (11.9%), coxsackievirus B2 (6.3%), and echovirus 6 (6.1%) ( Table 2 Editorial Note: Serotype-based enterovirus surveillance in the United States has five objectives. First, NESS data help to determine long-term patterns of circulation for individual serotypes (4) . Second, the data are used to associate trends in enteroviral diseases with circulating serotypes such as viral meningitis-associated hospitalizations during periods of high activity of echoviruses 9 and 30 and lower numbers of these cases for years when group B coxsackieviruses predominate (CDC, unpublished data, 1988 (CDC, unpublished data, -1999 . Third, the data are used to guide outbreak investigations. Fourth, because different serotypes have differential sensitivity to at least one candidate antienterovirus drug (5), information on circulating serotypes helps guide the development of new diagnostic tests and therapies. Finally, NESS monitors circulation of poliovirus strains to supplement poliovirus surveillance; this aspect of enterovirus surveillance will remain important until successful global poliovirus eradication ends the need for polio surveillance.
The findings in this report are consistent with previous observations on temporal variability of predominant serotypes. Of the 15 serotypes reported most commonly during 2000-2001, seven (coxsackieviruses A9, B2, and B4 and echoviruses 6, 9, 11, and 30) have appeared consistently among the 15 most common serotypes each year during 1993-1999 (6,7). Two enteroviruses (echovirus 18 and echovirus 13) that previously were rarely reported emerged as the predominant serotypes in 2001. Timely identification of increased activity by these serotypes helped guide investigation of outbreaks of aseptic meningitis reported to CDC in 2001 from six states (Alaska, Louisiana, Maryland, Mississippi, Montana, and Tennessee); all of these outbreaks were linked subsequently to one or both of these serotypes (8) . For echovirus 13, this was the first report of widespread circulation in the United States and probably reflected the worldwide activity of this serotype that has been observed since 2000 (8) .
Multiple factors might explain the increase in unknown serotypes, including limited availability of the appropriate typing antisera, high cost of reagents, and labor intensity of testing. The use of enterovirus typing based on genomic sequencing (9) could increase the proportion of identified serotypes, including those for which reagents are not readily available. The virtual absence of vaccine-related poliovirus isolates after 2000 is associated with the discontinuation of the use of oral polio vaccine in the United States beginning in 2000 (10) .
The findings in this report are subject to at least two limitations. First, because of the voluntary and passive nature of NESS, the small number of reports for some states, and the lack of reporting or testing by others, these results might not be fully representative of the entire United States. Second, because many serotypes were not identified, the number of individual enteroviruses might be underestimated.
As laboratory participation in NESS increases, the data will become more representative geographically. More timely reporting from laboratories would allow NESS to provide frequent feedback in the form of an online enterovirus surveillance summary, which would increase the public health utility of this surveillance system. 
West Nile Virus

United States
During November 14-20, a total of 111 laboratorypositive human cases of WNV-associated illness were reported from Indiana (n=37), Illinois (n=23), Texas (n=17), Nebraska (n=nine), Ohio (n=six), Georgia (n=five), Arkansas (n=four), Florida (n=four), Minnesota (n=three), Maryland (n=one), Massachusetts (n=one), and Tennessee (n=one). During the same period, WNV infections were reported in 90 dead crows and 330 other dead birds. A total of 411 veterinary cases and 25 WNV-positive mosquito pools were reported.
During 2002, a total of 3,698 human cases with laboratory evidence of recent WNV infection have been reported from Illinois (n=761), Michigan (n=504), Ohio (n=419), Louisiana (n=323), Indiana (n=284), Mississippi (n=182), Missouri (n=169), Texas (n=165), Nebraska (n=124), New York (n=78), Kentucky (n=67), Pennsylvania (n=59), Tennessee (n=55), Iowa (n=48), Alabama (n=46), Minnesota (n=45), Wisconsin (n=42), South Dakota (n=37), Georgia (n=35), the District of Columbia (n=34), Maryland (n=29), Virginia (n=27), Arkansas (n=25), Massachusetts (n=23), Florida (n=22), Connecticut (n=17), North Dakota (n=17), Oklahoma (n=16), Colorado (n=12), New Jersey (n=12), Kansas (n=nine), West Virginia (n=three), North Carolina (n=two), California (n=one), Delaware (n=one), Montana (n=one), Rhode Island (n=one), South Carolina (n=one), Vermont (n=one), and Wyoming (n=one) (Figure 1 ). Among the 3,287 patients for whom data were available, the median age was 55 years (range: 1.5 months-99 years); 1,755 (54%) were male, and the dates of illness onset ranged from June 10 to 
Missouri
During January 1-November 9, 2002, the Missouri Department of Health and Senior Services (MDHSS) identified 168 persons with laboratory evidence of West Nile virus (WNV) infection; 34 cases were confirmed by CDC on the basis of the plaque-reduction neutralization test, and 134 cases were classified as probable pending CDC confirmation. Five cases were fatal; all five patients had encephalitis.
The 168 patients had a median age of 53.2 years (range: 4-92 years); 91 patients (53%) were male. Median age of decedents was 75.6 years (range: 61-88 years). Dates of illness onset ranged from July 31 to October 12.
Of Missouri's 114 reporting local public health agencies (LPHAs), 109 (96%) have reported WNV-positive animal tests, representing nearly all geographic regions and human population centers in Missouri (Figure 2 ). Human WNV cases have occurred among persons from 32 (28%) of LPHA districts; 126 (75%) patients resided in metropolitan St. Louis districts. The metropolitan Kansas City area has recorded eight cases; no human WNV cases have been reported from the Springfield area (Greene County).
The elevated WNV incidence rate in the metropolitan St. Louis area, especially within St. Louis city limits (16.1 cases per 100,000 population), is under investigation. Of 134 Missouri WNV cases for which case investigations are completed, 86 (64%) patients recalled being bitten by a mosquito 3 weeks before onset of illness. In addition, 86 (64%) patients reported not using repellent during that time.
Patients spent an average of 4.4 hours outdoors per day for leisure and work. Morning (47%) was the time that patients most frequently reported being active outdoors for leisure and work. A total of 58 (43%) patients reported having standing water around their home during the 3 weeks preceding onset of illness. The top four reported sources of standing water were birdbaths, flowerpots, pet watering containers, and tires.
MDHSS provides frequent updates on human cases of WNV and activity by county for dead birds and infected horses on its website (http://www.dhss.state.mo.us/westnilevirus/ positives.pdf ). Results on specimens submitted for laboratory testing are provided to patient providers, submitting laboratories, and local health departments. MDHSS issues press releases updating case numbers, reminding the public of personal protection measures, and advising elimination of sources of standing water around residences. MDHSS produced a statewide prevention campaign based on the slogan "Don't Let It Bug You," which included posters and brochures distributed to all 114 LPHAs, direct-mail appeals to St. Louis area clergy for increased community awareness of mosquito habitats, television and radio public service announcements, and a toll-free hotline for citizens' questions. Mosquitocontrol program recommendations, developed by MDHSS Persons whose rapid-test results are reactive should be counseled about their likelihood of being infected with HIV and precautions to prevent HIV transmission, but they should return for definitive test results before medical referrals or partner counseling is initiated (3). A simple message to convey this information could be a statement that "Your preliminary test result was positive, but we won't know for sure if you are HIV-infected until we get the results from your confirmatory test. In the meantime, you should take precautions to avoid possibly transmitting the virus."
The Public Health Service recommends that rapid HIV tests should be used and preliminary positive test results provided when tested persons might benefit (1) . Decisions about whether to use rapid tests should be based on considerations of return rates for standard test results and urgency of the need for test results (i.e., when necessary to make decisions about postexposure or perinatal prophylaxis) (1, 4, 5) . The use of rapid tests will facilitate the acceptance of HIV testing and improve receipt of results in other health-care settings in which HIV testing is recommended, such as hospitals and acutecare clinics, where persons who are unaware of their HIV status might seek health-care services (6) . Additional information and guidance on the use of rapid HIV tests are available from CDC at http://www.cdc.gov/hiv/testing.htm.
Sites wanting to perform this new HIV-1 rapid test that are not already certified to perform moderate-complexity laboratory tests under CLIA must enroll in the CLIA program, administered by the Centers for Medicare and Medicaid Services. The application and state agency contact information are available at http://www.cms.hhs.gov/clia. Information about enrollment and the requirements for moderatecomplexity testing are available at http://www.phppo.cdc.gov/ clia/default.asp.
CLIA moderate-complexity requirements provide minimum standards for personnel, quality control, proficiency testing, and quality assurance. In addition, some states have specific requirements that might apply to laboratory testing in general or to HIV testing specifically.
* Sensitivity is the probability that the test result will be reactive if the specimen is a true positive; specificity is the probability that the test result will be nonreactive if the specimen is a true negative. † The predictive value of a screening test is the probability that the test accurately predicts the true infection status of the person tested. Use of a rapid test that allows same-day results can substantially increase the number of persons who receive their test results, which improves the delivery of counseling and treatment services (1) . On the basis of data submitted by the manufacturer for test approval, the sensitivity* of OraQuick in the clinical studies performed was 99.6% (95% confidence interval [CI]=98.5%-99.9%), and specificity was 100% (95% CI=99.7%-100%), comparable to those of FDA-approved enzyme immunoassays in widespread use. Because HIV prevalence is low in most U.S. testing settings, the negative predictive value † of screening with a single rapid test is high. Therefore, a negative rapid HIV test does not require further testing, and negative results with counseling can be provided at the initial visit. Retesting is recommended for those persons with a recent (within 3 months) history of known or possible exposure to HIV because there might have been insufficient time for detectable antibodies to develop (2 Cefixime is the only CDC-recommended oral antimicrobial agent to which Neisseria gonorrhoeae has not developed significant resistance (1) . Uncomplicated N. gonorrhoeae infections may be treated with single-dose regimens of cefixime 400 mg orally, ceftriaxone 125 mg intramuscularly, or an oral fluoroquinolone (ciprofloxacin 500 mg, levofloxacin 250 mg, or ofloxacin 400 mg). However, fluoroquinolones should not be used for treatment of gonorrhea if the infection was acquired in Asia, the Pacific Islands (including Hawaii), or California because the prevalence of fluoroquinoloneresistant N. gonorrhoeae is high in those areas (1, 2) .
In the absence of cefixime, the primary recommended treatment option for gonorrhea in Hawaii and California is ceftriaxone. Also, in the absence of cefixime, ceftriaxone is the only CDC-recommended gonorrhea treatment option for young children and pregnant women throughout the United States. Fluoroquinolones can continue to be used for treating gonorrhea in areas of the United States with low prevalence of fluoroquinolone-resistant N. gonorrhoeae, but antimicrobial susceptibility monitoring should routinely be performed (2) . Other oral antimicrobial agents, such as cefpodoxime, cefuroxime axetil, and azithromycin, are not recommended by CDC for the treatment of gonorrhea. Additional information on the use of oral antimicrobials in treating N. gonorrhoeae infections will be available from CDC at http://www.cdc.gov/ std.
Erratum: Vol. 51, No. 45
In the report "Influenza Outbreak-Madagascar, JulyAugust, 2002," in Figure 2 on page 1017, the number of districts with laboratory-confirmed influenza was incorrectly indicated. Because a limited number of patients in a few districts were tested for influenza, the map has been changed to depict only districts with reported influenza-like illness cases. 60  44  73  103  116  78  163  162  3  39  Alaska  -1  --3  2  2  1  --Hawaii  1  5  8  6  N  N  7  11  2  7 Guam - 
